Quick filters

67 trials match your criteria

Duchenne muscular dystrophy+1

Not yet recruiting

Study on the Safety and Effectiveness of Delandistrogene Moxeparvovec for Patients with Duchenne Muscular Dystrophy

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years

Muscular dystrophy

Not yet recruiting

Study on the Safety of ATA-200 Gene Therapy for Patients with Limb-Girdle Muscular Dystrophy Type R5

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years

Dermatomyositis

Not recruiting

Study on the Effects of Human Normal Immunoglobulin in Adults with Dermatomyositis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years

Dermatomyositis+3

Not recruiting

Phase 2 Study of Daxdilimab with Prednisone in Adults with Inadequately Controlled Dermatomyositis or Anti‑Synthetase Inflammatory Myositis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years

Dermatomyositis

Not recruiting

A study testing brepocitinib compared to placebo for adults with dermatomyositis to see if it works and is safe

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years

Study of BMN 351 given by intravenous infusion to evaluate safety and tolerability in patients with Duchenne Muscular Dystrophy

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years

Study on the Effects of Casimersen and Golodirsen for Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping

Investigational
Countries:ItalyItaly
  • Participants:0–17 years

Study on the Effectiveness and Safety of Losmapimod for Patients with Facioscapulohumeral Muscular Dystrophy (FSHD)

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years

Study on the Safety and Effects of Delandistrogene Moxeparvovec in Children Under 4 with Duchenne Muscular Dystrophy

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years

Study on the Effects and Safety of Efgartigimod PH20 SC for Adults with Active Idiopathic Inflammatory Myopathy

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years

Study on the Effects of Satralizumab in Children and Adolescents with Duchenne Muscular Dystrophy

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years

powered byClinicalTrials.eu